Method and apparatus for pacing during revascularization

Abstract
Cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia associated with an ischemic event including the occlusion of a blood vessel during a revascularization procedure. Pacing pulses are generated from a pacemaker and delivered through one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device used in the revascularization procedure. The pacemaker generates the pacing pulses according to a predetermined cardiac protection pacing sequence before, during, and/or after the ischemic event.
Description
TECHNICAL FIELD

This document relates generally to cardiac pacing systems and particularly to a system for delivering pacing pulses during a revascularization procedure.


BACKGROUND

The heart is the center of a person's circulatory system. It includes an electro-mechanical system performing two major pumping functions. The left portions of the heart draw oxygenated blood from the lungs and pump it to the organs of the body to provide the organs with their metabolic needs for oxygen. The right portions of the heart draw deoxygenated blood from the body organs and pump it to the lungs where the blood gets oxygenated. These pumping functions are resulted from contractions of the myocardium (cardiac muscles). In a normal heart, the sinoatrial node, the heart's natural pacemaker, generates electrical impulses, called action potentials, that propagate through an electrical conduction system to various regions of the heart to excite the myocardial tissues of these regions. Coordinated delays in the propagations of the action potentials in a normal electrical conduction system cause the various portions of the heart to contract in synchrony to result in efficient pumping functions. A blocked or otherwise abnormal electrical conduction and/or deteriorated myocardial tissue cause dyssynchronous contraction of the heart, resulting in poor hemodynamic performance, including a diminished blood supply to the heart and the rest of the body. The condition where the heart fails to pump enough blood to meet the body's metabolic needs is known as heart failure.


Myocardial infarction (MI) is the necrosis of portions of the myocardial tissue resulted from cardiac ischemia, a condition in which the myocardium is deprived of adequate oxygen and metabolite removal due to an interruption in blood supply caused by an occlusion of a blood vessel such as a coronary artery. The necrotic tissue, known as infarcted tissue, loses the contractile properties of the normal, healthy myocardial tissue. Consequently, the overall contractility of the myocardium is weakened, resulting in an impaired hemodynamic performance. Following an MI, cardiac remodeling starts with expansion of the region of infarcted tissue and progresses to a chronic, global expansion in the size and change in the shape of the entire left ventricle. The consequences include a further impaired hemodynamic performance and a significantly increased risk of developing heart failure.


When a blood vessel such as the coronary artery is partially or completely occluded, a revascularization procedure such as percutaneous transluminal coronary angioplasty (PCTA) can be performed to reopen the occluded blood vessel. However, the revascularization procedure itself involves a temporary occlusion of the coronary artery. In addition, plaques dislodged and displaced by the revascularization procedure may enter small blood vessels branching from the blood vessel in which the revascularization is performed, causing occlusion of these small blood vessels. This complication is referred to as “snow plow effect.” The revascularization procedure may also cause distal embolization, i.e., obstruction of the artery caused by the plaque dislodged during the procedure. The temporary occlusion, snow plow effect, and distal embolization may each cause cardiac injuries such as further expansion of the region of infarcted tissue. In addition, the revascularization procedure is known to increase the risk for occurrences of arrhythmia.


Therefore, there is a need for minimizing cardiac injury and preventing arrhythmias during the revascularization procedure.


SUMMARY

Cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia associated with an ischemic event including the occlusion of a blood vessel during a revascularization procedure. Pacing pulses are generated from a pacemaker and delivered through one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device used in the revascularization procedure. The pacemaker generates the pacing pulses according to a predetermined cardiac protection pacing sequence before, during, and/or after the ischemic event.


In one embodiment, a pacemaker includes a pacing output circuit and a control circuit. The control circuit includes a cardiac protection pacing sequence timer that times a predetermined cardiac protection pacing sequence. The predetermined cardiac protection pacing sequence includes alternating pacing and non-pacing periods. The pacing periods each have a predetermined pacing duration during which a plurality of pacing pulses are delivered from the pacing output circuit in a predetermined pacing mode. The non-pacing periods each have a predetermined non-pacing duration during which no pacing pulse is delivered.


In one embodiment, a PTVI device includes a proximal end portion, a distal end portion, and an elongate body. The proximal end portion includes one or more connectors for connecting to a pacemaker. The distal end portion is configured for intravascular placement. The elongate body is coupled between the proximal end portion and the distal end portion. One or more pacing electrodes are incorporated onto the distal end portion. One or more conductors within the elongate body each connect one of the one or more pacing electrodes to one of the one or more connectors. In a further embodiment, the distal end portion includes a tip and an angioplasty device. The angioplasty device has one end approximately adjacent to the tip and another end coupled to the elongate body.


In one embodiment, a method for operating a system providing for cardiac protection pacing is provided. A predetermined pacing sequence is timed. The predetermined pacing sequence includes alternating pacing and non-pacing periods. The pacing periods each have a predetermined pacing duration during which a plurality of pacing pulses are delivered in a predetermined pacing mode. The plurality of pacing pulses are delivered to one or more pacing electrodes incorporated onto a PTVI device.


In one embodiment, a method for making a PTVI device is provided. The PTVI device has a distal end portion configured for intravascular placement. One or more pacing electrodes are incorporated onto that distal end portion.


This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects of the invention will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof. The scope of the present invention is defined by the appended claims and their legal equivalents.





BRIEF DESCRIPTION OF THE DRAWINGS

The drawings illustrate generally, by way of example, various embodiments discussed in the present document. The drawings are for illustrative purposes only and may not be to scale.



FIG. 1 is an illustration of an embodiment of a system providing for pacing during revascularization and portions of an environment in which the system is used.



FIG. 2 is an illustration of an embodiment of a pacemaker providing for pacing during revascularization.



FIG. 3 is a timing diagram illustrating an exemplary embodiment of a cardiac protection pacing sequence for the pacing during revascularization.



FIG. 4 is an illustration of an embodiment of a PTVI device with pacing electrodes.



FIG. 5 is an illustration of another embodiment of a PTVI device with pacing electrodes.



FIG. 6 is an illustration of another embodiment of a PTVI device with pacing electrodes.



FIG. 7 is an illustration of an exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 8 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 9 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 10 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 11 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 12 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).



FIG. 13 is an illustration of another exemplary specific embodiment of the distal end portion of a PTVI device with pacing electrode(s).





DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their legal equivalents.


It should be noted that references to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment.


This document discusses a pacing system for minimizing damage to the myocardial tissue and preventing arrhythmias during a revascularization procedure that requires temporary occlusion of one or more blood vessels. In a specific application, this system provides for cardiac protection pacing during a percutaneous transluminal coronary angioplasty (PTCA) procedure. Cardiac protection pacing includes the delivery of a pacing therapy before, during, and/or after the temporary occlusion of a coronary artery associated with the PTCA procedure, for preventing or reducing adverse effects of the occlusion, which is an ischemic event. The pacing therapy can be delivered at almost any time during a revascularization procedure, as soon as pacing electrodes are in place, without substantially interfering with the revascularization procedure.


To deliver pacing pulses during a revascularization procedure, one or more pacing electrodes are incorporated onto the distal end portion of a PTVI device. Examples of such PTVI device include guide wires, dilatation balloon catheters, stent delivery systems, brachytherapy devices, atherectomy devices, distal embolization protection devices, and guiding catheters. A pacemaker is connected to the proximal end portion of the PTVI device to deliver the pacing pulses to the heart through the one or more electrodes. In one embodiment, the pacemaker is an external pacing device such as a pacing system analyzer. This approach to cardiac protection pacing allows delivery of pacing pulses as soon as the PTVI device is inserted.



FIG. 1 is an illustration of an embodiment of a system 100 providing for pacing during revascularization and portions of an environment in which system 100 is used. System 100 includes a PTVI device 110, a pacemaker 130, and a cable 125 connecting PTVI device 110 and pacemaker 130. When needed, system 100 also includes a reference electrode 122, which is a surface electrode, such as a skin patch electrode, connected to a lead 120. Lead 120 is connected to a connector 118 allowing its connection to cable 125.


PTVI device 110 is used during a revascularization procedure and includes a distal end portion 111 for intravascular placement and a proximal end portion 112. Proximal end portion 112 includes a proximal end device 114 and pacing connectors 116 and 117. Proximal end device 114 includes various connectors and other structures allowing manipulation of PTVI device 110 including the percutaneous transluminal insertion of the device and operation of an angioplasty device at distal end 111. Pacing connectors 116 and 117 provide for electrical connections between cable 125 and PTVI device 110. In one embodiment, as illustrated in FIG. 1, PTVI device 110 is a percutaneous transluminal coronary angioplasty (PTCA) device used in a PTCA procedure. During the PTCA procedure, an opening 105 is made on a femoral artery 104 in a patient's body 102. PTVI device 110 is inserted into femoral artery 104 and advanced to an aorta 106 and then to a right coronary artery 107, which is narrowed or blocked. The angioplasty device at distal end 111 is then used to open up the blocked right coronary artery 107. In another embodiment, PTVI device 110 is used to open up a blocked left coronary artery 108.


Distal end portion 111 of PTVI device 110 includes one or more pacing electrodes to allow pacing pulses to be delivered to a heart 101 during the PTCA procedure. In one embodiment, pacing pulses are delivered through two pacing electrodes on distal end portion 111 of PTVI device 110. In another embodiment, pacing pulses are delivered through a pacing electrode on distal end portion 111 of PTVI device 110 and surface electrode 122 functioning as the return electrode for pacing.


Pacemaker 130 delivers pacing pulses by following a cardiac protection pacing sequence. In one embodiment, the cardiac protection pacing sequence provides for cardiac protection pacing following an ischemic event to prevent arrhythmias and cardiac injuries caused by the ischemic event. In one embodiment, pacemaker 130 is an external pacemaker such as a pacing system analyzer (PSA). In another embodiment, pacemaker 130 includes an implantable pacemaker adapted for external use.


It is to be understood that FIG. 1 is for illustrative, but not restrictive, purposes. For example, the physical structure of proximal end portion 112 depends on functional and ease-of-use considerations. Proximal end device 114 represents a structure that accommodates all the mechanical connection and access requirements, which depend on the specific configuration and function of PTVI device 110. In one embodiment, proximal end device 114 includes an integrated device as illustrated in FIG. 1. In another embodiment, proximal end device 114 branches out into multiple connectors and/or other devices. Pacing connectors 116 and 117 represent a structure that accommodates all the electrical connections required for delivering pacing pulses from pacemaker 130 to PTVI device 110. The number of pacing connectors depends on the number of pacing electrodes incorporated onto PTVI device 110 and how it is to be connected to cable 125. In one embodiment, when more than one electrical connection is incorporated onto PTVI device 110, proximal end portion 112 includes branched-out pacing connectors such as pacing connectors 116 and 117 as illustrated in FIG. 1. In another embodiment, proximal end portion 112 includes a single connector providing for multiple, independent electrical connections.



FIG. 2 is an illustration of an embodiment of a pacemaker 230 that provides for pacing during revascularization. Pacemaker 230 is a specific embodiment of pacemaker 130 and includes a pacing output circuit 232 and a control circuit 234. In one embodiment, pacemaker 230 further includes a user interface to allow a user to control the delivery of the pacing pulses by controlling the pacing parameters and/or the timing of the delivery.


Pacing output circuit 232 delivers pacing pulses to PTVI device 110 through cable 125. Control circuit 234 controls the delivery of the pacing pulses. In one embodiment, as illustrated in FIG. 2, control circuit 234 includes a cardiac protection pacing sequence timer 236, which times a predetermined cardiac protection pacing sequence. The cardiac protection pacing sequence is predetermined to provide cardiac protection pacing before, during, and/or after an ischemic event such as the occlusion of a coronary artery by PTVI device 110 during a PTCA procedure.



FIG. 3 is a timing diagram illustrating an exemplary embodiment of a cardiac protection pacing sequence for pacing during a revascularization procedure such as a PTCA procedure. The cardiac protection pacing sequence is initiated after a time interval 340, which starts when the insertion of PTVI device into body 102 is completed. Time interval 340 expires before, during, and/or after an ischemic event that occurs when the blood vessel at the revascularization site is substantially occluded by PTVI device 110. In one embodiment, the cardiac protection pacing sequence is applied repeatedly, before, during, and/or after the ischemic event, during the revascularization procedure.


In the embodiment illustrated in FIG. 3, the cardiac protection pacing sequence includes alternating pacing and non-pacing periods. Each pacing period is a pacing duration during which the pacing pulses are delivered in a predetermined pacing mode. The non-pacing period is a non-pacing duration during which no pacing pulses is delivered. In one embodiment, during each pacing period, rapid, asynchronous pacing is applied. In other words, pacing pulses are delivered at a rate substantially higher than the patient's intrinsic heart rate without being synchronized to the patient's intrinsic cardiac contractions. For illustrative purpose only, FIG. 3 shows a cardiac protection pacing sequence that includes two cycles of alternating pacing and non-pacing periods: pacing period 342A, non-pacing periods 344A, pacing period 342B, and non-pacing periods 344B. In one embodiment, the number of the cycles of alternating pacing and non-pacing periods is programmable, and each of the pacing and non-pacing periods is programmable. In one embodiment, the cardiac protection pacing sequence is initiated before the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 30 seconds to 20 minutes. The non-pacing period is in a range of approximately 30 seconds to 20 minutes. In a specific example, the cardiac protection pacing sequence initiated before the ischemic event includes 3 cycles of alternating pacing and non-pacing periods each being approximately 5-minute long. In one embodiment, the cardiac protection pacing sequence is initiated during the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 30 seconds to 20 minutes. The non-pacing period is in a range of approximately 30 seconds to 20 minutes. In a specific example, the cardiac protection pacing sequence delivered during the ischemic event includes 3 cycles of alternating pacing and non-pacing periods each being approximately 5-minute long. In one embodiment, the cardiac protection pacing sequence is initiated after the ischemic event and includes approximately 1 to 4 cycles of alternating pacing and non-pacing periods. The pacing period is in a range of approximately 10 seconds to one minute. The non-pacing period is in a range of approximately 10 seconds to one minute. In one specific example, the cardiac protection pacing sequence delivered after the ischemic event includes 2 to 4 cycles of alternating pacing and non-pacing periods each being approximately 30-second long.


In various other embodiments, the cardiac protection pacing sequence includes pacing at one or more atrial tracking or other pacing modes. Examples of pacing modes used in such a cardiac protection pacing sequence include VDD, VVI, and DDD modes. In various embodiments, the VVI and DDD modes are delivered with a lower rate limit higher than the patient's intrinsic heart rate. In one embodiment, pacing therapy is delivered to prevent restenosis. In another embodiment, pacing therapy is delivered to treat an arrhythmia during the revascularization procedure, for example, when the patient experiences bradycardia during the procedure.


In one embodiment, the pacing pulses are delivered according to the cardiac protection pacing sequence through PTVI device 110 during the revascularization procedure. After the revascularization procedure, if an implantable pacemaker is implanted into the patient, pacing therapy is delivered to heart 101 through one or more implantable leads from the implantable pacemaker. The pacing therapy includes delivering pacing pulses according to a pacing sequence that is substantially identical or similar to the cardiac protection pacing sequence applied during the revascularization procedure. The pacing sequence is delivered according to a predetermined schedule, such as on a predetermined periodic basis. This prevents or reduces possible cardiac injury after the revascularization, including cardiac injury and occurrences of arrhythmia caused by ischemic events including myocardial infarction that may be experienced by the patient after the implantation of the implantable pacemaker.



FIG. 4 is an illustration of an embodiment of a PTVI device 410. PTVI device 410 is a specific embodiment of PTVI device 110 and has an elongate body 450 between a distal end portion 451 and a proximal end portion 452. Distal end portion 451 is configured for intravascular placement and includes a distal tip 453. Distal tip 453 includes a pacing electrode 454. A conductor 456 extends longitudinally within elongate body 450 and connected between pacing electrode 454 and a connector 458, which is part of proximal end portion 452.


In one embodiment, elongate body 450 is an elongate cylindrical shaft having a diameter in a range of approximately 0.2 mm to 1.5 mm, and PTVI device 410 has a length in a range of approximately 30 cm to 300 cm. In another embodiment, elongate body 450 is an elongate tubular body having an outer diameter in a range of approximately 0.5 mm to 8 mm and an inner diameter (of a lumen) in a range of approximately 0.4 mm to 7 mm. In one embodiment, PTVI device 410 is a guide wire such as a coronary guide wire. PTVI device 410 is formed by conductor 456, which is insulated throughout its length except for pacing electrode 454 and connector 458. As the core of the guide wire, conductor 456 is made of a metallic material such as stainless steel, alloys of nickel, titanium, and cobalt, and is insulated with a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE). Electrode 454 is made of a metallic material such as platinum, and iridium alloy. In another embodiment, conductor 456 is a metal wire other than the core of the guide wire. In another embodiment, PTVI device 410 is a guiding catheter such as a coronary guiding catheter. The coronary guiding catheter includes an elongate tubular body with a lumen extending between distal end portion 452 and proximal end portion 452. In another embodiment, PTVI device 410 includes two or more electrodes in distal end portion 451 and two or more conductors each connected between one of the electrodes and connector 458, which is a multi-conductor connector allowing for two or more electrically insulated connections.



FIG. 5 is an illustration of another embodiment of a PTVI device 510. PTVI device 510 is another specific embodiment of PTVI device 110 and has an elongate body 550 between a distal end portion 551 and a proximal end portion 552. Distal end portion 551 is configured for intravascular placement and includes a distal tip 553 and an angioplasty device 560. Angioplasty device 560 has one end approximately adjacent to distal tip 553 and another end coupled to elongate body 550. In various embodiments, angioplasty device 560 allows for application of an angioplasty therapy such as vascular dilatation, stent delivery, brachytherapy (radiotherapy), atherectomy, or embolic protection. In one embodiment, angioplasty device 560 includes an adjustable portion that has controllable expandability and contractibility. In one specific embodiment, angioplasty device 560 includes a balloon that is inflated and deflated through a passageway longitudinally extending within elongate body 550 and connected between the chamber of the balloon and a connector at proximal end portion 552. The balloon is inflatable using an air pump connected to that connector. In one embodiment, distal tip 553 is a tapered tip that facilitates the insertion of PTVI device 510 into a blood vessel. A pacing electrode 554A is approximately adjacent to one end of angioplasty device 560. Another pacing electrode 554B is approximately adjacent to the other end of angioplasty device 560. A conductor 556A extends longitudinally within elongate body 550 and is connected between pacing electrode 554A and a pacing connector 516, which is part of proximal end portion 552. A conductor 556B extends longitudinally within elongate body 550 and is connected between pacing electrode 554B and a pacing connector 517, which is also part of proximal end portion 552. In an alternative embodiment, pacing connectors 516 and 517 are physically integrated into one multi-conductor connector. Proximal end portion 552 also includes a proximal end device 514. Proximal end device 514 represents a structure that accommodates all the mechanical connection and access requirements, which depend on the function of angioplasty device 560. In one embodiment, proximal end device 514 includes an integrated device as illustrated in FIG. 5. in another embodiment, proximal end device 514 branches out into multiple connectors and/or other devices.


In one embodiment, elongate body 550 is an elongate cylindrical shaft having a diameter in a range of approximately 1 mm to 5 mm. PTVI device 510 has a length in a range of approximately 50 cm to 150 cm. In one embodiment, angioplasty device 560 has a fixed, substantially cylindrical shape with a diameter in a range of approximately 1 mm to 10 mm. In another embodiment, angioplasty device 560 has an adjustable, substantially cylindrical or semi-spherical shape with a maximum diameter in a range of approximately 1 mm to 10 mm when fully expanded and a maximum diameter in a range of approximately 0.5 mm to 5 mm when fully contracted. In one embodiment, PTVI device 510 is a PTCA catheter and includes a lumen longitudinally extending within elongate body 550 to accommodate at least a portion of a guide wire such as PTVI device 410. In one embodiment, conductors 556A and 556B are each made of a metallic material such as stainless steel and alloys of nickel, titanium, and cobalt. Electrodes 554A and 554B are each made of a metallic material such as platinum, and iridium alloy. Elongate body 550 has a tubular outer shell made of a material such as silicone, polyurethane, Teflon, and polytetrafluoroethylene (PTFE).


In one alternative embodiment, PTVI device 510 includes one electrode in distal end portion 551 and one conductor connected between that electrode and a pacing connector in proximal end portion 552. In another alternative embodiment, PTVI device 510 includes three or more electrodes in distal end portion 551 and three or more conductors each connected between one of the electrodes a pacing connector in proximal end portion 552.



FIG. 6 is an illustration of another embodiment of a PTVI device 610 with pacing electrodes. PTVI device 610 is another specific embodiment of PTVI device 110 and is similar to PTVI device 510 except for the location of the pacing electrodes. PTVI device 610 has a distal end portion 651, where pacing electrodes 654A and 654B are attached onto angioplasty device 560. In one specific embodiment, pacing electrodes 654A and 654B are each approximately adjacent to one end of angioplasty device 560.


PTVI devices 410, 510, and 610 are illustrated in FIGS. 4-6 for illustrative but not restrictive purposes. For example, the one or more pacing electrodes can be distributed on the distal portion of a PTVI device in any way allowing proper delivery of pacing pulses. In various embodiments, the one or more pacing electrodes can be distributed on the angioplasty device, the distal tip, and/or the elongate body at the distal end portion of the PTVI device.



FIGS. 7-13 illustrate exemplary specific embodiments of the distal end of a PTVI device with one or more pacing electrodes. In one embodiment, PTVI device 410, 510, and 610 are each made by modifying a selected product of Guidant Corporation's Vascular Intervention division (“Guidant VI,” Temecula, Calif.) to include one or more pacing electrodes. Examples of such a selected product are illustrated in FIGS. 7-13. According to the present subject matter, one or more pacing electrodes are incorporated onto any PTVI device as deemed appropriate by one skilled in the art. Such PTVI devices include, but are not limited to, devices that belong to the same category as those illustrated in FIGS. 7-13.



FIG. 7 is an illustration of an embodiment of the distal end portion 751, which is an exemplary specific embodiment of distal end portion 451. Distal end portion 751 is the distal portion of a coronary guide wire (Guidant VI's HI-TORQUE PILOT™ 50 Guide Wire with Hydrocoat hydrophilic coating) modified to include a pacing electrode 754. The coronary guide wire includes an elongate body 750 being an insulated conductive wire that extends to a distal tip 751 The coronary guide wire has a length of approximately 190cm or 300 cm, depending on the specific product model, and a diameter of approximately 0.014 inches (0.3556 mm). The conductive wire is connected to pacing electrode 754 at the distal end of distal tip 753. Distal end portion 751 also includes a radiopaque marker 762, which allows for measurement of lesion length. In one embodiment, the single-electrode configuration allows the coronary guide wire to have a relatively small diameter. In one embodiment, pacing pulses are delivered using a unipolar electrode configuration, with a return electrode such as reference electrode 122.



FIG. 8 is an illustration of an embodiment of the distal end portion 851, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 851 is the distal portion of a coronary dilatation balloon catheter (Guidant VI's VOYAGER™ RX Coronary Dilatation Catheter) modified to include pacing electrodes 854A and 854B. Distal end portion 851 is extended from an elongate body 850 and includes a tapered tip 853 and an angioplasty device 860. The coronary dilatation balloon catheter has a usable catheter working length of approximately 143 cm and accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the catheter. Elongate body 850 includes a shaft having a diameter in a range of approximately 2.0 to 2.8 French, depending on the specific product model. Angioplasty device 860 is a specific embodiment of angioplasty device 560 and includes an adjustable balloon 864 that is approximately adjacent to tapered tip 853. Adjustable balloon 864 is used for coronary dilatation by inflation. When inflated, adjustable balloon 864 has a diameter in a range of 1.5 mm to 4 mm, depending on the specific product model. Pacing electrode 854A is approximately adjacent to one end of adjustable balloon 864. Pacing electrode 854B is approximately adjacent to the other end of adjustable balloon 864. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 854A and 854B, a unipolar configuration using one of pacing electrodes 854A and 854B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 9 is an illustration of an embodiment of the distal end portion 951, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 951 is the distal portion of a stent delivery platform (Guidant VI's GUIDANT MULTI-LINK RX ULTRA™ Coronary Stent System) modified to include pacing electrodes 954A and 954B. Distal end portion 951 is extended from an elongate body 950 and includes a tip 953 and an angioplasty device 960. The stent delivery platform accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the device. Angioplasty device 960 is a specific embodiment of angioplasty device 560 and includes an adjustable balloon 964 that is approximately adjacent to tip 953. Adjustable balloon 964 is used for placing a stent in the coronary artery where distal end portion 951 has reached. Depending on the specific product model, the working size of adjustable balloon 964 accommodates stents having a diameter in a range of approximately 3.5 mm to 5 mm and a length in a range of approximately 13 mm to 38 mm. Pacing electrode 954A is approximately adjacent to one end of adjustable balloon 964. Pacing electrode 954B is approximately adjacent to the other end of adjustable balloon 964. Distal end portion 951 also includes a pair of radiopaque markers 962A and 962B on adjustable balloon 964 for indicating the balloon's working length. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 954A and 954B, a unipolar configuration using one of pacing electrodes 954A and 954B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 10 is an illustration of an embodiment of the distal end portion 1051, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 1051 is the distal portion of a brachytherapy device (Guidant VI's GALILEO® Intravascular Radiotherapy System) modified to include pacing electrodes 1054A and 1054B. Distal end portion 1051 is extended from an elongate body 1050 and includes a tapered tip 1053 and an angioplasty device 1060. The brachytherapy device accommodates a guide wire having a maximum diameter of 0.014 inches (0.3556 mm), such as the coronary guide wire illustrated in FIG. 7, that is used for insertion of the device. Angioplasty device 1060 is a specific embodiment of angioplasty device 560 and includes an brachytherapy device 1066 that is approximately adjacent to tapered tip 1053 and includes a chamber containing an radiological agent to provide therapeutic doses to the tissue area where distal end portion 1051 has reached. Brachytherapy device 1066 has diameter in a range of approximately 2.5 mm, 3.0 mm, or 3.5 mm and a therapeutic dose length of approximately 32 mm or 52 mm, depending on the specific product model. Pacing electrode 1054A is approximately adjacent to one end of brachytherapy device 1066. Pacing electrode 1054B is approximately adjacent to the other end of brachytherapy device 1066. Distal end portion 1051 also includes a pair of radiopaque markers 1062A and 1062B on brachytherapy device 1066 for indicating the therapeutic dose length. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1054A and 1054B, a unipolar configuration using one of pacing electrodes 1054A and 1054B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 11 is an illustration of an embodiment of the distal end portion 1151, which is an exemplary specific embodiment of distal end portion 551. Distal end portion 1151 is the distal portion of an atherectomy device (Guidant VI's FLEXI-CUT® Directional Debulking System) modified to include pacing electrodes 1154A and 1154B. Distal end portion 1151 is extended from an elongate body 1150 and includes a tapered tip 1153 and an angioplasty device 1160. The atherectomy device has a working length of approximately 134 cm. Angioplasty device 1160, which is a specific embodiment of angioplasty device 560, is an atherectomy device that includes a cylindrical nosecone 1168 that is approximately adjacent to tapered tip 1153 and a cutter 1170 connected to cylindrical nosecone 1168. Cutter 1170 cuts the plaques that block or narrow the portion of the coronary artery where distal end portion 1151 has reached. Cylindrical nosecone 1168 stores the cut plaques. Depending on the specific product model, atherectomy device is capable of operating in blood vessels having diameters ranging from approximately 2.5 mm to 4 mm. Pacing electrode 1154A is on tapered tip 1153 and approximately adjacent to the distal end of cylindrical nosecone 1168. Pacing electrode 1154B is on cutter 1170 and approximately adjacent to the distal end of cutter 1170. Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1154A and 1154B, a unipolar configuration using one of pacing electrodes 1154A and 1154B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 12 is an illustration of an embodiment of the distal end portion 1251, which is an exemplary specific embodiment of distal end portion 551, Distal end portion 751 is the distal portion of a distal embolization protection device (Guidant VI's RX ACCUNET™ Embolic Protection System) modified to include pacing electrodes 1254A and 1254B. Distal end portion 1251 is extended from an elongate body 1250 and includes a tip 1253 and an angioplasty device 1260. Elongate body 1250 is based on a coronary guide wire that has a diameter of 0.014 inches (0.3556 mm) and extends throughout substantially the full length of the distal embolization protection device, which is either 190 cm or 300 cm, depending on the specific product model. Angioplasty device 1260, which is a specific embodiment of angioplasty device 560, is an embolic protection device that includes a filter basket 1272 with a filter membrane 1274 to contain and remove embolic material including plaques dislodged during the angioplasty procedure. Filter basket 1272 is flexible, with available basket diameters (when fully expanded) of 4.5 mm, 5.5mm, 6.5 mm, and 7.5 mm, depending on the specific product model. Pacing electrode 1254A is on tip 1253. Pacing electrode 1254B is on elongate body 1250 and is approximately adjacent to the proximal end of filter basket 1272, Pacing pulses are delivered using a bipolar configuration with pacing electrodes 1254A and 1254B, a unipolar configuration using one of pacing electrodes 1254A and 1254B and a return electrode such as reference electrode 122, or a combination of bipolar and unipolar configurations.



FIG. 13 is an illustration of an embodiment of the distal end portion 1351, which is another exemplary specific embodiment of distal end portion 451. Distal end portion 1351 is the distal portion of a coronary guiding catheter (Guidant VI's VIKING OPTIMA™ 50 Guiding Catheter) modified to include a pacing electrode 1354. The coronary guiding catheter includes a tubular elongate body 1350 that has a distal tip 1353, and a lumen having a diameter of 6 French (0.068 inches), 7 French (0.078 inches), or 8 French (0.091 inches). In one embodiment, the single-electrode configuration allows the coronary guiding catheter to have a relatively small diameter. In one embodiment, pacing pulses are delivering using a unipolar electrode configuration, with a return electrode such as reference electrode 122.


It is to be understood that the above detailed description, including the various configurations of PTVI devices, is intended to be illustrative, and not restrictive. In general, cardiac protection pacing is applied to prevent or reduce cardiac injury and/or occurrences of arrhythmia caused by an ischemic event by using one or more pacing electrodes incorporated onto any intravascular device and a pacemaker that is capable of delivering pacing pulses according to a predetermined cardiac protection pacing sequence. Other embodiments will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. A method for pacing during a revascularization procedure, comprising: timing a predetermined first pacing sequence configured to prevent cardiac injury caused by occlusion of a coronary artery during the revascularization procedure, the predetermined first pacing sequence including alternating first pacing periods and first non-pacing periods, the first pacing periods each having a predetermined first pacing duration during which a first plurality of pacing pulses are delivered in a predetermined first pacing mode, the first non-pacing periods each having a predetermined first non-pacing duration during which no pacing pulse is delivered; anddelivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto a percutaneous transluminal vascular intervention (PTVI) device.
  • 2. The method of claim 1, wherein timing the predetermined first pacing sequence comprises timing the first pacing periods each in a range of approximately 10 seconds to 20 minutes and timing the first non-pacing periods each in a range of approximately 10 seconds to 20 minutes.
  • 3. The method of claim 2, wherein delivering the first plurality of pacing pulses comprises programming a pacing rate to a rate that is substantially higher than an intrinsic heart rate.
  • 4. The method of claim 1, wherein delivering the first plurality of pacing pulses comprises delivering the first plurality of pacing pulses before an ischemic event during the revascularization procedure using the PTVI device, the ischemic event caused by the occlusion of the coronary artery during the revascularization procedure.
  • 5. The method of claim 1, wherein delivering the first plurality of pacing pulses comprises delivering the first plurality of pacing pulses during an ischemic event during the revascularization procedure using the PTVI device, the ischemic event caused by the occlusion of the coronary artery during the revascularization procedure.
  • 6. The method of claim 1, wherein delivering the first plurality of pacing pulses comprises delivering the first plurality of pacing pulses after an ischemic event during the revascularization procedure using the PTVI device, the ischemic event caused by the occlusion of the coronary artery during the revascularization procedure.
  • 7. The method of claim 1, further comprising delivering a second plurality of pacing pulses to one or more pacing electrodes incorporated onto an implantable pacing lead.
  • 8. The method of claim 7, wherein delivering the second plurality of pacing pulses comprises delivering a predetermined second pacing sequence including alternating second pacing periods and second non-pacing periods, the second pacing periods each having a predetermined second pacing duration during which a second plurality of pacing pulses are delivered in a predetermined second pacing mode, the second non-pacing periods each having a predetermined second non-pacing duration during which no pacing pulse is delivered.
  • 9. The method of claim 1, wherein delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto the PTVI device comprises delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto a guide wire.
  • 10. The method of claim 1, wherein delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto the PTVI device comprises delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto a guide catheter.
  • 11. The method of claim 1, wherein delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto the PTVI device comprises delivering the first plurality of pacing pulses to one or more pacing electrodes incorporated onto a PTVI device including an angioplasty device.
  • 12. A system for use during revascularization of a coronary artery, comprising: a pacemaker including; a pacing output circuit; anda control circuit coupled to the pacing output circuit, the control circuit including a cardiac protection pacing sequence timer configured to time a predetermined cardiac protection pacing sequence configured to prevent cardiac injury caused by occlusion of the coronary artery during the revascularization, the cardiac protection pacing sequence including alternating pacing and non-pacing periods, the pacing periods each having a predetermined pacing duration during which a plurality of pacing pulses are delivered from the pacing output circuit in a predetermined pacing mode, the non-pacing periods each having a predetermined non-pacing duration during which no pacing pulse is delivered; anda percutaneous transluminal vascular intervention (PTVI) device including one or more pacing electrodes, the PTVI device configured to be coupled to the pacemaker to allow the plurality of pacing pulses to be delivered from the pacing output circuit to the one or more pacing electrodes during the revascularization.
  • 13. The system of claim 12, wherein the PTVI device comprises a guide wire.
  • 14. The system of claim 12, wherein the PTVI device comprises a guiding catheter.
  • 15. The system of claim 12, wherein the PTVI device comprises an angioplasty device.
  • 16. The system of claim 15, wherein the angioplasty device comprises a dilation balloon.
  • 17. The system of claim 15, wherein the angioplasty device comprises a stent delivery platform.
  • 18. The system of claim 15, wherein the angioplasty device comprises an atherectomy device.
  • 19. The system of claim 15, wherein the angioplasty device comprises an embolization protection device.
  • 20. The method of claim 11, wherein delivering the first plurality of pacing pulses to one or more pacing electrodes comprises delivering the first plurality of pacing pulses to pacing electrodes attached onto the angioplasty device.
CLAIM OF PRIORITY

This application is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 11/113,828, filed on Apr. 25, 2005, now issued as U.S. Pat. No. 7,962,208, which is hereby incorporated by reference herein in its entirety.

US Referenced Citations (231)
Number Name Date Kind
3769984 Muench Nov 1973 A
3837347 Tower Sep 1974 A
3865118 Bures Feb 1975 A
3893461 Preston Jul 1975 A
3915174 Preston Oct 1975 A
3942536 Mirowski et al. Mar 1976 A
3949757 Sabel Apr 1976 A
4030508 Thalen Jun 1977 A
4094321 Muto Jun 1978 A
4124031 Mensink et al. Nov 1978 A
4136702 Trabucco Jan 1979 A
4202339 Wirtzfeld et al. May 1980 A
4262982 Kenny Apr 1981 A
4365639 Goldreyer Dec 1982 A
4388930 De Bellis Jun 1983 A
4587975 Salo et al. May 1986 A
4702253 Nappholz et al. Oct 1987 A
4763655 Wirtzfeld et al. Aug 1988 A
4809697 Causey, III et al. Mar 1989 A
4834710 Fleck May 1989 A
4882777 Narula Nov 1989 A
4919133 Chiang Apr 1990 A
4955382 Franz et al. Sep 1990 A
4962767 Brownlee Oct 1990 A
5007427 Suzuki et al. Apr 1991 A
5025786 Siegel Jun 1991 A
5072458 Suzuki Dec 1991 A
5099839 Miyata et al. Mar 1992 A
5111818 Suzuki et al. May 1992 A
5121750 Katims Jun 1992 A
5127403 Brownlee Jul 1992 A
5131406 Kaltenbach Jul 1992 A
5143089 Alt Sep 1992 A
5154169 Miyata et al. Oct 1992 A
5154387 Trailer Oct 1992 A
5156157 Valenta, Jr. et al. Oct 1992 A
5170802 Mehra Dec 1992 A
5261419 Osypka Nov 1993 A
5285781 Brodard Feb 1994 A
5314460 Borghi May 1994 A
5334221 Bardy Aug 1994 A
5336251 Borghi Aug 1994 A
5356427 Miyata et al. Oct 1994 A
5374287 Rubin Dec 1994 A
5387232 Trailer Feb 1995 A
5411535 Fujii et al. May 1995 A
5423806 Dale et al. Jun 1995 A
5466255 Franchi Nov 1995 A
5476502 Rubin Dec 1995 A
5483022 Mar Jan 1996 A
5484419 Fleck Jan 1996 A
5496354 DeBellis Mar 1996 A
5507787 Borghi Apr 1996 A
5531779 Dahl et al. Jul 1996 A
5545191 Mann et al. Aug 1996 A
5571159 Alt Nov 1996 A
5588432 Crowley Dec 1996 A
5634899 Shapland et al. Jun 1997 A
5674217 Wahlstrom et al. Oct 1997 A
5755761 Obino May 1998 A
5755764 Schroeppel May 1998 A
5760341 Laske et al. Jun 1998 A
5772693 Brownlee Jun 1998 A
5797903 Swanson et al. Aug 1998 A
5800496 Swoyer et al. Sep 1998 A
5814076 Brownlee Sep 1998 A
5843132 Ilvento Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5906207 Shen May 1999 A
5921935 Hickey Jul 1999 A
5935160 Auricchio et al. Aug 1999 A
5954761 Machek et al. Sep 1999 A
5997536 Osswald et al. Dec 1999 A
6014579 Pomeranz et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6056742 Murphy-Chutorian et al. May 2000 A
6132390 Cookston et al. Oct 2000 A
6156061 Wallace et al. Dec 2000 A
6161029 Spreigl et al. Dec 2000 A
6167315 Coe et al. Dec 2000 A
6178354 Gibson Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6238390 Tu et al. May 2001 B1
6241727 Tu et al. Jun 2001 B1
6272379 Fischell et al. Aug 2001 B1
6324434 Coe et al. Nov 2001 B2
6366808 Schroeppel et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6397109 Cammilli et al. May 2002 B1
6451016 Karakozian Sep 2002 B1
6477402 Lynch et al. Nov 2002 B1
6477427 Stolz et al. Nov 2002 B1
6501983 Natarajan et al. Dec 2002 B1
6512957 Witte Jan 2003 B1
6540765 Malacoff Apr 2003 B1
6569145 Shmulewitz et al. May 2003 B1
6584362 Scheiner et al. Jun 2003 B1
6638278 Falwell et al. Oct 2003 B2
6640120 Swanson et al. Oct 2003 B1
6690970 Taheri et al. Feb 2004 B1
6697676 Dahl Feb 2004 B2
6709390 Marie Pop Mar 2004 B1
6711436 Duhaylongsod Mar 2004 B1
6711440 Deal et al. Mar 2004 B2
6772014 Coe et al. Aug 2004 B2
6813516 Ujhelyi et al. Nov 2004 B2
6865420 Kroll Mar 2005 B1
6909920 Lokhoff et al. Jun 2005 B2
6950701 Begemann et al. Sep 2005 B2
6980858 Fuimaono et al. Dec 2005 B2
6988001 Greatbatch et al. Jan 2006 B2
6994314 Garnier et al. Feb 2006 B2
6999809 Currier et al. Feb 2006 B2
6999821 Jenney et al. Feb 2006 B2
7003350 Denker et al. Feb 2006 B2
7029467 Currier et al. Apr 2006 B2
7236821 Cates et al. Jun 2007 B2
7295874 Prinzen et al. Nov 2007 B2
7422585 Eggers et al. Sep 2008 B1
7499756 Bowe et al. Mar 2009 B2
7570981 Peterson Aug 2009 B2
7917210 Baynham et al. Mar 2011 B2
7962208 Shuros et al. Jun 2011 B2
7979123 Prinzen et al. Jul 2011 B2
8027723 Pastore et al. Sep 2011 B2
8214040 Pastore et al. Jul 2012 B2
8244352 Eidenschink et al. Aug 2012 B2
20020026228 Schauerte Feb 2002 A1
20020042632 Iaizzo et al. Apr 2002 A1
20020072777 Lu Jun 2002 A1
20020095067 Guenst et al. Jul 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20030004549 Hill et al. Jan 2003 A1
20030009189 Gilson et al. Jan 2003 A1
20030045908 Condie et al. Mar 2003 A1
20030060854 Zhu Mar 2003 A1
20030078471 Foley et al. Apr 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030125774 Salo Jul 2003 A1
20030139778 Fischell et al. Jul 2003 A1
20030158583 Burnett et al. Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030204206 Padua et al. Oct 2003 A1
20030204231 Hine et al. Oct 2003 A1
20030212361 Boyle et al. Nov 2003 A1
20030229386 Rosenman et al. Dec 2003 A1
20030233130 Padmanabhan et al. Dec 2003 A1
20040010189 van Sloun et al. Jan 2004 A1
20040015081 Kramer et al. Jan 2004 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040038947 Wink et al. Feb 2004 A1
20040088017 Sharma et al. May 2004 A1
20040106960 Siejko et al. Jun 2004 A1
20040116994 De Bellis Jun 2004 A1
20040133247 Stahmann et al. Jul 2004 A1
20040162599 Kurth Aug 2004 A1
20040172081 Wang Sep 2004 A1
20040214148 Salvino et al. Oct 2004 A1
20040215139 Cohen Oct 2004 A1
20040255956 Vinten-Johansen et al. Dec 2004 A1
20040267326 Ocel Dec 2004 A1
20050004476 Payvar et al. Jan 2005 A1
20050038345 Gorgenberg et al. Feb 2005 A1
20050075673 Warkentin et al. Apr 2005 A1
20050119545 Swanson Jun 2005 A1
20050137483 Fischell et al. Jun 2005 A1
20050137631 Yu et al. Jun 2005 A1
20050137647 Wallace et al. Jun 2005 A1
20050143780 Henry et al. Jun 2005 A1
20050149155 Scheiner et al. Jul 2005 A1
20050197674 McCabe et al. Sep 2005 A1
20050222632 Obino Oct 2005 A1
20050251239 Wallace et al. Nov 2005 A1
20050288717 Sunagawa Dec 2005 A1
20050288763 Andreas et al. Dec 2005 A1
20060009830 Atkinson et al. Jan 2006 A1
20060036306 Heist et al. Feb 2006 A1
20060058597 Machado et al. Mar 2006 A1
20060100639 Levin et al. May 2006 A1
20060100669 Fuimaono et al. May 2006 A1
20060116593 Zhang et al. Jun 2006 A1
20060136049 Rojo Jun 2006 A1
20060142660 Maschke Jun 2006 A1
20060142812 Ortega et al. Jun 2006 A1
20060149326 Prinzen et al. Jul 2006 A1
20060178586 Dobak Aug 2006 A1
20060184191 O'Brien Aug 2006 A1
20060195038 Carlson et al. Aug 2006 A1
20060241357 Chirife Oct 2006 A1
20060241704 Shuros et al. Oct 2006 A1
20060241733 Zhang et al. Oct 2006 A1
20060241736 Haldeman Oct 2006 A1
20060247700 Jackson Nov 2006 A1
20060253156 Pastore et al. Nov 2006 A1
20060259085 Zhang et al. Nov 2006 A1
20060259087 Baynham et al. Nov 2006 A1
20060259088 Pastore et al. Nov 2006 A1
20060287684 Baynham et al. Dec 2006 A1
20060293741 Johnson et al. Dec 2006 A1
20070021789 Pastore et al. Jan 2007 A1
20070054871 Pastore et al. Mar 2007 A1
20070055334 Haldeman et al. Mar 2007 A1
20070100410 Lamson et al. May 2007 A1
20070150005 Sih et al. Jun 2007 A1
20070150009 Kveen et al. Jun 2007 A1
20070233200 Maschke Oct 2007 A1
20080058757 Pajunk et al. Mar 2008 A1
20080071315 Baynham et al. Mar 2008 A1
20080082136 Gaudiani Apr 2008 A1
20080109063 Hancock et al. May 2008 A1
20080114408 Shuros et al. May 2008 A1
20080288030 Zhang et al. Nov 2008 A1
20080319502 Sunagawa et al. Dec 2008 A1
20090005845 David et al. Jan 2009 A1
20090143835 Pastore et al. Jun 2009 A1
20090318943 Eidenschink et al. Dec 2009 A1
20090318984 Mokelke et al. Dec 2009 A1
20090318989 Tomaschko et al. Dec 2009 A1
20090318990 Tomaschko et al. Dec 2009 A1
20090318991 Tomaschko et al. Dec 2009 A1
20090318992 Eidenschink et al. Dec 2009 A1
20090318993 Eidenschink et al. Dec 2009 A1
20090318994 Eidenschink et al. Dec 2009 A1
20100056858 Mokelke et al. Mar 2010 A1
20100130913 Baynham et al. May 2010 A1
20110137363 Baynham et al. Jun 2011 A1
20110144709 Baynham et al. Jun 2011 A1
Foreign Referenced Citations (33)
Number Date Country
2459408 Mar 2003 CA
3300050 Jul 1984 DE
1690566 Aug 2006 EP
5245215 Sep 1993 JP
7504597 May 1995 JP
2002514478 May 2002 JP
2004533297 Nov 2004 JP
2006-516451 Jul 2006 JP
2011524787 Sep 2011 JP
WO-9518649 Jul 1995 WO
WO-9958191 Nov 1999 WO
WO-0115609 Mar 2001 WO
WO-03035139 May 2003 WO
WO-2004012811 Feb 2004 WO
WO-2004058326 Jul 2004 WO
WO-2004058326 Jul 2004 WO
WO-2004096290 Nov 2004 WO
WO-2005000206 Jan 2005 WO
WO-2005042083 May 2005 WO
WO-2005065771 Jul 2005 WO
WO-2006060586 Jun 2006 WO
WO-2006115693 Nov 2006 WO
WO-2006115693 Nov 2006 WO
WO-2006116205 Nov 2006 WO
WO-2006124636 Nov 2006 WO
WO-2006124636 Nov 2006 WO
WO-2006124729 Nov 2006 WO
WO-2006124729 Nov 2006 WO
WO-2007133962 Nov 2007 WO
WO-2007133962 Nov 2007 WO
WO-2008027261 Mar 2008 WO
WO-2009154730 Dec 2009 WO
WO-2009154720 Dec 2009 WO
Non-Patent Literature Citations (171)
Entry
“U.S. Appl. No. 11/030,575, Non-Final Office Action mailed Jul. 26, 2006”, 10 pgs.
“U.S. Appl. No. 11/030,575, Response filed Oct. 26, 2006 to Non Final Office Action mailed Jul. 26, 2006”, 8 pgs.
“U.S. Appl. No. 11/113,828, Advisory Action mailed Feb. 2, 2010”, 3 pgs.
“U.S. Appl. No. 11/113,828, Examiner Interview Summary received Feb. 4, 2011”, 1 pg.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Jun. 29, 2009”, 11 pgs.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Nov. 24, 2009”, 13 pgs.
“U.S. Appl. No. 11/113,828, Non-Final Office Action mailed Mar. 5, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Non-Final Office Action mailed Dec. 22, 2008”, 10 pgs.
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Feb. 4, 2011”, 7 pgs.
“U.S. Appl. No. 11/113,828, Notice of Allowance mailed Oct. 19, 2010”, 4 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jan. 25, 2010 to Final Office Action mailed Nov. 24, 2009”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jan. 28, 2008 to Restriction Requirement mailed Dec. 26, 2007”, 7 pgs.
“U.S. Appl. No. 11/113,828, Response filed Mar. 23, 2009 to Non-Final Office Action mailed Dec. 22, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Jun. 5, 2008 to Non-Final Office Action mailed Mar. 5, 2008”, 8 pgs.
“U.S. Appl. No. 11/113,828, Response filed Oct. 29, 2009 to Final Office Action mailed Jun. 29, 2009”, 9 pgs.
“U.S. Appl. No. 11/113,828, Response filed Nov. 17, 2008 to Final Office Action mailed Sep. 17, 2008”, 11 pgs.
“U.S. Appl. No. 11/113,828, Restriction Requirement mailed Dec. 26, 2007”, 8 pgs.
“U.S. Appl. No. 11/129,050, Advisory Action mailed Jul. 14, 2009”, 3 pgs.
“U.S. Appl. No. 11/129,050, Examiner Interview Summary mailed Feb. 11, 2009”, 2 pgs.
“U.S. Appl. No. 11/129,050, Final Office Action mailed Apr. 21, 2009”, 10 pgs.
“U.S. Appl. No. 11/129,050, Final Office Action mailed May 12, 2008”, 8 pgs.
“U.S. Appl. No. 11/129,050, Non-Final Office Action mailed Nov. 6, 2008”, 7 pgs.
“U.S. Appl. No. 11/129,050, Non-Final Office Action mailed Nov. 26, 2007”, 7 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Apr. 1, 2010”, 6 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Jul. 16, 2010”, 4 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Aug. 24, 2009”, 7 pgs.
“U.S. Appl. No. 11/129,050, Notice of Allowance mailed Dec. 2, 2009”, 4 pgs.
“U.S. Appl. No. 11/129,050, Response filed Feb. 23, 2009 to Non-Final Office Action mailed Nov. 6, 2008”, 13 pgs.
“U.S. Appl. No. 11/129,050, Response filed Feb. 26, 2008 to Non-Final Office Action mailed Nov. 26, 2007”, 14 pgs.
“U.S. Appl. No. 11/129,050, Response filed Jun. 22, 2009 to Final Office Action mailed Apr. 21, 2009”, 9 pgs.
“U.S. Appl. No. 11/129,050, Response filed Jul. 14, 2008 to Final Office Action mailed May 12, 2008”, 13 pgs.
“U.S. Appl. No. 11/129,050, Response filed Sep. 28, 2007 to Restriction Requirement mailed Aug. 1, 2007”, 11 pgs.
“U.S. Appl. No. 11/129,050, Supplemental Amendment and Response filed Sep. 12, 2008 to Final Office Action mailed May 12, 2008 and the Advisory Action mailed Jul. 28, 2008”, 12 pgs.
“U.S. Appl. No. 11/129,058, Advisory Action mailed Oct. 17, 2010”, 3 pgs.
“U.S. Appl. No. 11/129,058, Appeal Brief filed Jan. 8, 2008”, 23 pgs.
“U.S. Appl. No. 11/129,058, Decision on Appeal mailed Nov. 4, 2009”, 15 pgs.
“U.S. Appl. No. 11/129,058, Examiner's Answer to Appeal Brief mailed Jun. 18, 2008”, 14 pgs.
“U.S. Appl. No. 11/129,058, Final Office Action mailed Jul. 9, 2007”, 12 pgs.
“U.S. Appl. No. 11/129,058, Non-Final Office Action mailed Jan. 29, 2007”, 11 pgs.
“U.S. Appl. No. 11/129,058, Office Communication mailed Jan. 15, 2010”, 2 pgs.
“U.S. Appl. No. 11/129,058, Response filed Apr. 30, 2007 to Non Final Office Action mailed Jan. 29, 2007”, 16 pgs.
“U.S. Appl. No. 11/129,058, Response filed Oct. 9, 2007 to Final Office Action mailed Jul. 9, 2007”, 14 pgs.
“U.S. Appl. No. 11/382,849, Final Office Action mailed Jan. 28, 2010”, 7 pgs.
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed May 12, 2010”, 5 pgs.
“U.S. Appl. No. 11/382,849, Non-Final Office Action mailed Aug. 31, 2009”, 8 pgs.
“U.S. Appl. No. 11/382,849, Response filed Apr. 26, 2010 to Final Office Action mailed Jan. 28, 2010”, 10 pgs.
“U.S. Appl. No. 11/382,849, Response filed Jun. 8, 2009 to Restriction Requirement mailed May 6, 2009”, 8 pgs.
“U.S. Appl. No. 11/382,849, Response filed Aug. 2, 2010 to Non Final Office Action mailed May 12, 2010”, 7 pgs.
“U.S. Appl. No. 11/382,849, Response filed Nov. 30, 2009 to Non Final Office Action mailed Aug. 31, 2009”, 11 pgs.
“U.S. Appl. No. 11/382,849, Restriction Requirement mailed May 6, 2009”, 6 pgs.
“U.S. Appl. No. 11/468,875, Advisory Action mailed Aug. 19, 2010”, 3 pgs.
“U.S. Appl. No. 11/468,875, Final Office Action mailed Jun. 1, 2009”, 6 pgs.
“U.S. Appl. No. 11/468,875, Non-Final Office Action mailed Dec. 11, 2008”, 8 pgs.
“U.S. Appl. No. 11/468,875, Response filed Mar. 9, 2009 to Non-Final Office Action mailed Dec. 11, 2008”, 10 pgs.
“U.S. Appl. No. 11/468,875, Response filed Sep. 1, 2009 to Advisory Action mailed Aug. 19, 2009 and the Final Office Action mailed Jun. 1, 2009”, 9 pgs.
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Mar. 24, 2010”, 7 pgs.
“U.S. Appl. No. 11/868,767, Notice of Allowance mailed Sep. 17, 2010”, 4 pgs.
“Arrow Bipolar Pacing Catheters and Pacing Kits”, Arrow International, (2000), 4 pgs.
“Australian Application Serial No. 2007290672, First Examiner Report Received mailed Aug. 23, 2010”, 2 pgs.
“Coronary Dilatation Catheters”, online]. [archived Mar. 3, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060303151627/http://www.guidant.com/products/TemplatePDFs/NoPriceDilataticatheters.pdf>, (2006), 3 pgs.
“European Application Serial No. 06740227.1, Communication dated Dec. 27, 2007”, 2 pgs.
“European Application Serial No. 06740227.1, Response filed Jan. 27, 2008 to Communication dated Dec. 27, 2007”, 9 pgs.
“European Application Serial No. 06752527.9, Communication mailed Mar. 8, 2010”, 6 pgs.
“European Application Serial No. 06752527.9, Response filed Jul. 7, 2010 to Office Action dated Mar. 8, 2010”, 15 pgs.
“European Application Serial No. 06752527.9, Summons to Attend Oral Proceedings Received mailed Jul. 23, 2010”, 3 pgs.
“European Application Serial No. 06752540.2, Communication Mar. 3, 2008”, 2 pgs.
“European Application Serial No. 06752540.2, Communication mailed Mar. 8, 2010”, 2 pgs.
“European Application Serial No. 06752540.2, Response filed Apr. 9, 2008 to Communication Mar. 3, 2008”, 6 pgs.
“European Application Serial No. 06752540.2, Response filed Jul. 15, 2010 to Communication mailed Mar. 8, 2010”, 20 pgs.
“European Application Serial No. 06762527.9, Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 2 pgs.
“European Application Serial No. 06762527.9, Response filed Apr. 9, 2008 to Communication pursuant to Rules 161 to 182 EPC mailed Mar. 3, 2008”, 6 pgs.
“European Application Serial No. 07797336.0, Communication mailed Mar. 10, 2010”, 3 pgs.
“European Application Serial No. 07797336.0, Office Action mailed Feb. 24, 2009”, 4 pgs.
“European Application Serial No. 07797336.0, Response filed Jul. 6, 2009 to Communication mailed Feb. 24, 2009”, 20 pgs.
“European Application Serial No. 07797336.0, Response filed Jul. 7, 2010 to Office Action dated Mar. 10, 2010”, 5 pgs.
“European Application Serial No. 07837205.9, Communication dated Apr. 8, 2009”, 2 pgs.
“Guidant Product Catalog”, [online]. [archived Feb. 4, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050204225345/http://guidant.com/products/VIproductcatalog.pdf>, (2005), 133 pgs.
“International Application Serial No. PCT/US/2009/003589, International Search Report mailed Sep. 14, 2009”, 5 pgs.
“International Application Serial No. PCT/US/2009/003589, Written Opinion mailed Sep. 14, 2009”, 11 pgs.
“International Application Serial No. PCT/US2006/018497, International Search Report mailed Oct. 24, 2006”, 5 pgs.
“International Application Serial No. PCT/US2006/018497, Written Opinion mailed Oct. 24, 2006”, 7 pgs.
“International Application Serial No. PCT/US2006/018642, International Search Report mailed Oct. 24, 2006”, 5 pgs.
“International Application Serial No. PCT/US2006/018642, Written Opinion mailed Oct. 24, 2006”, 7 pgs.
“International Application Serial No. PCT/US2006/018642,, International Search Report and Written Opinion mailed Oct. 24, 2006”, 14 pgs.
“International Application Serial No. PCT/US2007/018577, International Search Report mailed Jan. 15, 2008”, 4 pgs.
“International Application Serial No. PCT/US2007/018577, Written Opinion mailed Jan. 15, 2008”, 7 pgs.
“International Application Serial No. PCT/US2007/068217, International Search Report mailed Oct. 30, 2007”, 5 pgs.
“International Application Serial No. PCT/US2007/068217, Written Opinion mailed Oct. 30, 2007”, 8 pgs.
“International Application Serial No. PCT/US2009/003575, International Search Report mailed Sep. 14, 2009”, 6 pgs.
“International Application Serial No. PCT/US2009/003575, Written Opinion mailed Sep. 14, 2009”, 9 pgs.
“International Application Serial No. PCT/US2009/003577, International Search Report mailed Aug. 9, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003577, Written Opinion mailed Aug. 9, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003581, International Search Report mailed Sep. 21, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003581, Written Opinion mailed Sep. 21, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003590, International Search Report mailed Sep. 14, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003590, Written Opinion mailed Sep. 14, 2009”, 10 pgs.
“International Application Serial No. PCT/US2009/003594, International Search Report mailed Sep. 17, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/003594, Written Opinion mailed Sep. 17, 2009”, 9 pgs.
“International Search Report and Written Opinion for Application No. PCT/US2006/011972 mailed Oct. 6, 2006”, 16 pgs.
“Japanese Application Serial No. 2008-511421, Voluntary Amendment filed Apr. 27, 2009”, (w/ English Translation of Amended Claims), 11 pgs.
“Japanese Application Serial No. 2008-511452, Voluntary Amendment filed May 11, 2009”, (w/ English Translation of Amended Claims), 8 pgs.
“Japanese Application Serial No. 2009-510093, Voluntary Amendment filed Jan. 14, 2009”, 4 pgs.
“Product Overview: RX ACCULINK Carotid Stent System: RX ACCUNET Embolic Protection System”, [online]. [retrieved Apr. 14, 2006]. Retrieved from the Internet: <URL: http://web.archive.org/web/20060414151850/http://www.guidant.com/webapp/emarketing/ppt/acculink/ACCULINK.pdf>, (2005), 23 pgs.
“RX ACCUNET Embolic Protection System”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/ES/accunet.shtml>, (2006), 4 pgs.
“RX ACCUNET Embolic Protection System: Information for Prescribers”, [online]. [archived Feb. 5, 2005]. Retrieved from the Internet: <URL: http://web.archive.org/web/20050205044138/http://guidant.com/products/TemplatePDFs/ACCUNET—RX.pdf, (Jan. 6, 2005), 32 pgs.
“Voyager RX Coronary Dilatation Catheter”, [online]. [retrieved Jan. 11, 2006]. Retrieved from the Internet: <URL: http://www.guidant.com/products/ProductTemplates/VI/RX—US—Voyager—Intro.shtml>, (2006), 2 pgs.
Airaksinen, K. E., et al., “Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty”, J Am Coll Cardiol., 29(5), (Apr. 1997), 1035-1038.
Brockway, Marina V, et al., “Method and Apparatus for Delivering Chronic and Post-Ischemia Cardiac Therapies”, U.S. Appl. No. 11/207,251, filed Aug. 19, 2005, 40 pgs.
Girouard, Steven D., “Pulmonary Vein Stent for Treating Atrial Fibrillation”, U.S. Appl. No. 60/298,741, filed Jun. 15, 2001, 14 pgs.
Heinroth, K. M, et al., “Temporary transcoronary pacing by coated guidewires”, Clin Res Cardiol., 95, (2006), 1-6.
Henriques, Jose P., et al., “Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours”, J Am Coll Cardiol, 41(12), (Jun. 18, 2003), 2138-2142.
Kin, Hajime, et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion”, Cardiovascular Research, 62(1), (Apr. 1, 2004), 74-85.
Kis, A., “Repeated cardiac pacing extends the time during which canine hearts are protected against ischaemia-induced arrhythmias : role of nitric oxide.”, Journal of Molecular and Cellular Cardiology, 31(6), (Jun. 1999), 1229-1241.
Koning, M M, “Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels”, Circulation, 93(1), (Jan. 1, 1996), 178-186.
Meier, B., et al., “Coronary Pacing During Percutaneous Transluminal Coronary Angioplasty”, Circulation, 71(3), (Mar. 1985), 557-561.
Murry, C. E., et al., “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium”, Circulation, 74(5), (1986), 1124-1136.
Ovize, M., et al., “Stretch preconditions canine myocardium.”, Am J Physiol., 266(1 Pt 2), (Jan. 1994), H137-46.
Pastore, Joseph M, et al., “Intermittent Stress Augmentation Pacing for Cardioprotective Effect”, U.S. Appl. No. 11/458,286, filed Jul. 18, 2006, 23 pgs.
Rosa, A., et al., “Ectopic Pacing at Physiological Rate Improves Postanoxic Recovery of the Developing Heart”, Am. J. Physiol.—Heart Circ. Physiol., 284, (2003), H2384-H2392.
Tsang, A., et al., “Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway”, Circ Res., 95(3), Epub Jul. 8, 2004, (Aug. 6, 2004), 230-2.
Vanagt, W. Y. R., et al., “Ventricular Pacing for Improving Myocardial Tolerance to Ischemia”, Progress Report on Project Guidant-CARIM, (Oct. 2003), 1-25.
Vegh, A, et al., “Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning”, Cardiovascular Research, 25(12), (Dec. 1991), 1051-3.
Wu, Zhong-Kai, et al., “Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization”, Circulation, 106(24), (Dec. 10, 2002), 3091-3096.
Yang, S. M., et al., “Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways”, Journal of the American College of Cardiology, 44(5), (Sep. 1, 2004), 1103-1110.
Zhao, et al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning”, Am J Physiol Heart Circ Physiol, 285(2), (Aug. 2003), H579-H588.
“U.S. Appl. No. 13/029,631, Notice of Allowance mailed Aug. 24, 2012”, 7 pgs.
“U.S. Appl. No. 11/113,828, Final Office Action mailed Sep. 17, 2008”, 10 pgs.
“U.S. Appl. No. 11/468,875, Response filed Aug. 3, 2009 to Final Office Action mailed Jun. 1, 2009”, 8 pgs.
“U.S. Appl. No. 12/322,382, Advisory Action mailed Nov. 8, 2011”, 3 pgs.
“U.S. Appl. No. 12/322,382, Final Office Action mailed Aug. 25, 2011”, 12 pgs.
“U.S. Appl. No. 12/322,382, Non Final Office Action mailed Mar. 21, 2011”, 14 pgs.
“U.S. Appl. No. 12/322,382, Response filed Jun. 21, 2011, to Non Final Office Action mailed Mar. 21, 2011”, 16 pgs.
“U.S. Appl. No. 12/322,382, Response filed Oct. 24, 2011 to Final Office Action mailed Aug. 25, 2011”, 15 pgs.
“U.S. Appl. No. 12/694,328, Response filed Oct. 19, 2011 to Non Final Office Action mailed Aug. 19, 2011”, 13 pgs.
“U.S. Appl. No. 12/694,328, Response filed Nov. 21, 2011 to Advisory Action mailed Oct. 28, 2011”, and Non Final Office Action mailed Aug. 19, 2011, 13 pgs.
“U.S. Appl. No. 12/694,328, Advisory Action mailed Oct. 28, 2011”, 3 pgs.
“U.S. Appl. No. 12/694,328, Final Office Action mailed Aug. 19, 2011”, 12 pgs.
“U.S. Appl. No. 12/694,328, Non Final Office Action mailed Feb. 8, 2011”, 13 pgs.
“U.S. Appl. No. 12/694,328, Response filed Jun. 8, 2011 to Non Final Office Action mailed Feb. 8, 2011”, 12 pgs.
“Australian Application Serial No. 2007290672, Response filed Mar. 17, 2011 to Non Final Office Action mailed Aug. 23, 2011”, 11.
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 13, 2012”, English Translation only, 5 pgs.
“Chinese Application Serial No. 200780032286.X, Response filed Jun. 28, 2011, to Non Final Office Action dated Feb. 23, 2011”, (w/English Translation), 15 pgs.
“Chinese Application Serial No. 200780032286.X, Office Action mailed Feb. 23, 2011”, 5 pgs.
“European Application Serial No. 06740227.1, Office Action mailed Mar. 10, 2011”, 4 pgs.
“European Application Serial No. 06740227.1, Response filed Jul. 12, 2011 to Office Action dated Mar. 10, 2011”, 15 pgs.
“Japanese Application Serial No. 2008-508872, Office Action mailed Oct. 27, 2011”, 6 pgs.
“Japanese Application Serial No. 2008-508872, Response filed Jan. 31, 2012, to Office Action mailed Oct. 31, 2011”, W/English Translation, 14 pgs.
“Japanese Application Serial No. 2008-511421, Office Action mailed Nov. 16, 2011”, (w/ English Translation), 5 pgs.
“Japanese Application Serial No. 2008-511452, Office Action mailed Nov. 14, 2011”, 4 pgs.
“Japanese Application Serial No. 2008-511452, Response filed Feb. 14, 2012 to Office Action mailed Nov. 14, 2011”, (English Translation of Claims), 3 pgs.
“U.S. Appl. No. 12/484,727, Non Final Office Action mailed Feb. 13, 2012”, 7 pgs.
“U.S. Appl. No. 12/484,727, Response filed Jun. 12, 2012 to Non Final Office Action mailed Feb. 13, 2002”, 10 pgs.
“U.S. Appl. No. 12/484,727, Response filed Jan. 23, 2012 to Restriction Requirement mailed Dec. 23, 2011”, 6 pgs.
“U.S. Appl. No. 12/484,727, Restriction Requirement mailed Dec. 23, 2011”, 7 pgs.
“U.S. Appl. No. 12/484,804, Final Office Action mailed Jun. 5, 2012”, 10 pgs.
“U.S. Appl. No. 12/484,804, Response filed May 3, 2012 to Non-Final Office Action mailed Feb. 6, 2012”, 12 pgs.
“U.S. Appl. No. 12/484,804, Response filed Dec. 14, 2011 to Restriction Requirement mailed Nov. 14, 2011”, 7 pgs.
“U.S. Appl. No. 12/484,804, Restriction Requirement mailed Nov. 14, 2011”, 8 pgs.
“U.S. Appl. No. 12/484,804, Non Final Office Action mailed Feb. 6, 2012”, 8 pgs.
“European Application Serial No. 09767033.5, Office Action mailed Apr. 15, 2011”, 1 pg.
“European Application Serial No. 09767033.5, Response filed May 18, 2011 to Office Action mailed Apr. 15, 2011”, 7 pgs.
“European Application Serial No. 09767033.5, Response filed Dec. 5, 2011 to Office Action mailed Aug. 2, 2011”, 10 pgs.
“European Application Serial No. 09767043.4, Office Action mailed Apr. 14, 2011”, 1 pg.
“European Application Serial No. 09767043.4, Response filed May 24, 2011 to Office Action mailed Apr. 14, 2011”, 13 pgs.
“European Application Serial No. 09767033.5, Examination Notification Art 94(3) mailed Aug. 2, 2011”, 6 pgs.
“International Application Serial No. PCT/US2009/003577, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 12 pgs.
“International Application Serial No. PCT/US2009/003590, International Preliminary Report on Patentability mailed Jan. 6, 2011”, 9 pgs.
“Japanese Application Serial No. 2011-514591, Voluntary Amendment filed Jan. 12, 2011”, (w/ English Translation), 11 pgs.
“Japanese Application Serial No. 2011-514594, Voluntary Amendment filed Jan. 18, 2011”, (w/ English Translation of Amended Claims), 49 pgs.
“U.S. Appl. No. 13/019,888, Notice of Allowance mailed Nov. 6, 2012”, 8 pgs.
“U.S. Appl. No. 13/019,888, Response filed Sep. 28, 2012 to Non Final Office Action mailed Jun. 29, 2012”, 10 pgs.
Related Publications (1)
Number Date Country
20110230928 A1 Sep 2011 US
Continuations (1)
Number Date Country
Parent 11113828 Apr 2005 US
Child 13113706 US